What to look for in the new Tufts study on drug development costs. 10 issues.
When the new Tufts study on the costs of R&D for development of a new drug is released Tuesday at 10AM, here are 10 things to look for:
Author: James Love
Research note on oncology drugs, including trial size and orphan drug status
We will be sharing some data on 2005 to 2014 oncology approvals, including the size of the trials cited in the medical review, and the orphan status.
The spreadsheet we are working on updating is published here:
New leak of TPP consolidated text on intellectual property provides details of pandering to drug companies and publishers
For more information:
James Love, Knowledge Ecology International
email: james.love@keionline.org, +1.202.361.3040
The May 16, 2014 version of the consolidated negotiating text for the Intellectual Property Chapter for the Trans-Pacific Partnership (TPP) agreement is a long, complex document that taken as a whole is designed to expand and extend monopolies on knowledge goods, including in particular publisher-owned copyrights, patents on inventions, and monopoly rights in data used to register new drugs, vaccines and agricultural chemical products.
Matrix of Export Possibilities under Gilead HCV Licence
KEI was asked to make a presentation on Hepatitis C, on September 30, 2014, at a lunch seminar at UNITAID. I am attaching a PDF of the slides I used, as well as an eight page memo that takes a look at the recent Gilead license. The memo on the license was last edited on September 30, 2014, and is presented as a draft that may be revised in the future.
WIPO General Assembly: Worst ever?
|
| Brazil asks delegates to embrace work on copyright exceptions |
(More on Colombia here: